CVS Quote, Financials, Valuation and Earnings

Humana has a net margin of 0.09% compared to CVS Health's net margin of 1.63%. CVS Health's return on equity of 6.68% beat Humana's return on equity of 8.1%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.84%. On the other hand Humana has an analysts' consensus of $294.10 which suggests that it could grow by 16.4%. Given that CVS Health has higher upside potential than Humana, analysts believe CVS Health is more attractive than Humana.

CVS Health has a beta of 0.595, which suggesting that the stock is 40.471% less volatile than S&P 500. In comparison Humana has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.701%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.02%. Humana offers a yield of 1.4% to investors and pays a quarterly dividend of $0.89 per share. CVS Health pays 37.54% of its earnings as a dividend. Humana pays out 17.32% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than Humana quarterly revenues of $29.4B. CVS Health's net income of $87M is lower than Humana's net income of $480M. Notably, CVS Health's price-to-earnings ratio is 11.22x while Humana's PE ratio is 22.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 0.27x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 0.09% compared to CVS Health's net margin of 8.48%. CVS Health's return on equity of 6.68% beat Eli Lilly and's return on equity of 66.4%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.84%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 26.47%. Given that CVS Health has higher upside potential than Eli Lilly and, analysts believe CVS Health is more attractive than Eli Lilly and.

CVS Health has a beta of 0.595, which suggesting that the stock is 40.471% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.02%. Eli Lilly and offers a yield of 0.67% to investors and pays a quarterly dividend of $1.30 per share. CVS Health pays 37.54% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than Eli Lilly and quarterly revenues of $11.4B. CVS Health's net income of $87M is lower than Eli Lilly and's net income of $970.3M. Notably, CVS Health's price-to-earnings ratio is 11.22x while Eli Lilly and's PE ratio is 84.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 17.22x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Walgreens Boots Alliance has a net margin of 0.09% compared to CVS Health's net margin of -8%. CVS Health's return on equity of 6.68% beat Walgreens Boots Alliance's return on equity of -43.52%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.84%. On the other hand Walgreens Boots Alliance has an analysts' consensus of $10.36 which suggests that it could grow by 12.7%. Given that CVS Health has higher upside potential than Walgreens Boots Alliance, analysts believe CVS Health is more attractive than Walgreens Boots Alliance.

CVS Health has a beta of 0.595, which suggesting that the stock is 40.471% less volatile than S&P 500. In comparison Walgreens Boots Alliance has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.445%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.02%. Walgreens Boots Alliance offers a yield of 10.88% to investors and pays a quarterly dividend of $0.25 per share. CVS Health pays 37.54% of its earnings as a dividend. Walgreens Boots Alliance pays out -14.59% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than Walgreens Boots Alliance quarterly revenues of $37.5B. CVS Health's net income of $87M is higher than Walgreens Boots Alliance's net income of -$3B. Notably, CVS Health's price-to-earnings ratio is 11.22x while Walgreens Boots Alliance's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 0.05x for Walgreens Boots Alliance. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of 0.09% compared to CVS Health's net margin of -55.94%. CVS Health's return on equity of 6.68% beat SCWorx's return on equity of -80.46%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.84%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that CVS Health has higher upside potential than SCWorx, analysts believe CVS Health is more attractive than SCWorx.

CVS Health has a beta of 0.595, which suggesting that the stock is 40.471% less volatile than S&P 500. In comparison SCWorx has a beta of 2.839, suggesting its more volatile than the S&P 500 by 183.888%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.02%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 37.54% of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than SCWorx quarterly revenues of $759.7K. CVS Health's net income of $87M is higher than SCWorx's net income of -$425K. Notably, CVS Health's price-to-earnings ratio is 11.22x while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 0.71x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.